What did the retatrutide Phase 3 trials show?

The TRIUMPH-1 Phase 3 trial, published May 21, 2026, showed up to 30% mean body-weight reduction at 104 weeks in participants with severe obesity on retatrutide 9mg or 12mg. At 80 weeks, results were 17.6% (4mg), 23.7% (9mg), 25.0% (12mg) versus 3.9% placebo. TRIUMPH-4 confirmed approximately 29% weight loss at the highest dose. TRIUMPH-5 is a head-to-head comparison vs tirzepatide, with results pending.

When will retatrutide be FDA-approved?

There is no confirmed date. Based on the TRIUMPH-1 publication in May 2026 and the standard NDA review timeline (~12 months for Breakthrough Therapy after a Priority Review determination), a regulatory decision could plausibly come in 2027 — but this is speculative. Eli Lilly has not made a public NDA filing announcement as of July 2026. Monitoring Eli Lilly's press releases and FDA's drug approval database is the authoritative source.

How does retatrutide compare to semaglutide and tirzepatide?

Semaglutide (Wegovy) achieved approximately 15–17% weight loss in the STEP trial Phase 3 data. Tirzepatide (Zepbound) achieved approximately 20–22% in the SURMOUNT-1 Phase 3 trial. Retatrutide in TRIUMPH-1 reached approximately 25–30% at 104 weeks — a step up in efficacy at the highest doses. The mechanistic difference: semaglutide targets one receptor (GLP-1), tirzepatide targets two (GLP-1 + GIP), retatrutide targets three (GLP-1 + GIP + glucagon). The glucagon receptor arm adds thermogenic/energy-expenditure effects and also carries a heart-rate elevation signal not seen at the same level with the other agents.

Why does Titan sell retatrutide if it isn't FDA-approved?

Titan Peptide Lab supplies retatrutide as a research-use-only compound for in-vitro laboratory and pre-clinical research settings — the same status as the compound before FDA approval. This is an entirely separate channel from the clinical therapeutic space. Research scientists may legally acquire RUO compounds for research purposes; these are not sold as treatments, substitutes for approved medications, or for any human health purpose. The distinction between RUO supply and clinical use is absolute: Titan's retatrutide is not for human consumption.

retatrutide phase 3 · TRIUMPH trials · FDA timeline 2026 · research use only

Retatrutide Phase 3 results and FDA timeline — what the TRIUMPH trials showed.

On May 21, 2026, Eli Lilly published topline Phase 3 results from the TRIUMPH-1 trial for retatrutide, reporting up to 30% mean body-weight reduction at 104 weeks in participants with severe obesity on the highest dose — a number that approaches the outcomes seen with bariatric surgery. This page summarizes the published TRIUMPH trial data, the expected FDA submission timeline, and the honest status of retatrutide as of mid-2026: an investigational compound with exceptionally strong efficacy signals, still in the regulatory review pipeline, and not yet approved for any clinical use. Titan Peptide Lab supplies retatrutide strictly as a research-use-only reagent — not as a weight-loss medication, not as a clinical substitute for any approved treatment, and not for human consumption.

Retatrutide research vial — $199.99 How does retatrutide work?

TRIUMPH-1: up to 30% weight loss at 104 weeks (May 2026)

The TRIUMPH-1 Phase 3 trial enrolled 2,339 participants with severe obesity and randomized them to retatrutide 4mg, 9mg, 12mg, or placebo, titrating from 2mg over four weeks. Topline results published May 21, 2026 (Pharmaceutical Journal): at 80 weeks, 4mg achieved −17.6%, 9mg −23.7%, 12mg −25.0% versus −3.9% placebo. At 104 weeks, 9mg and 12mg reached approximately 30% mean body-weight reduction — a threshold no prior GLP-1 or dual incretin agent had cleared in a large Phase 3 trial. These are the strongest efficacy numbers in the obesity pharmacotherapy space to date. Retatrutide remains investigational.

Retatrutide mechanism explained →

TRIUMPH-4 and TRIUMPH-5 vs tirzepatide

TRIUMPH-4 interim data reported approximately 29% weight loss for the highest dose, confirming that the 30% signal in TRIUMPH-1 is reproducible across trial populations. TRIUMPH-5 is a direct head-to-head Phase 3 trial of retatrutide versus tirzepatide for obesity — a design that will directly answer the question 'does the third receptor arm (glucagon) add meaningful benefit over dual GIP/GLP-1 agonism in a randomized comparison?' Results from TRIUMPH-5 are pending as of July 2026. This is the most consequential ongoing incretin pharmacology trial in the field.

Retatrutide vs tirzepatide →

TRANSCEND-T2D-1: type 2 diabetes data (March 2026)

Separate from the obesity trials, TRANSCEND-T2D-1 tested retatrutide 12mg in participants with type 2 diabetes mellitus. Results published March 2026 showed −16.8% mean body weight at 40 weeks in the T2D population — lower than the non-diabetic obesity trials (expected, as T2D attenuates weight-loss response to GLP-1-class agents) but still a strong signal. This data supports a separate T2D indication in Eli Lilly's regulatory submission strategy, meaning retatrutide is being developed for both obesity and T2D, analogous to tirzepatide's Zepbound (obesity) and Mounjaro (T2D) dual-approval pathway.

Peptides for fat loss research →

FDA status: investigational — NDA not yet filed as of July 2026

Retatrutide holds Breakthrough Therapy Designation from the FDA — a recognition that the compound showed preliminary evidence of substantial improvement over existing therapies. Breakthrough designation accelerates review but does not guarantee approval and does not authorize clinical use. As of July 2026, Eli Lilly has not publicly announced an NDA filing date for retatrutide; the TRIUMPH-1 publication in May 2026 is consistent with a regulatory submission expected in late 2026 or 2027. Until an NDA is filed and approved, retatrutide is investigational and may only be used in licensed clinical trials or supplied as a research-use-only compound.

GLP-1 regulatory changes 2026 →

How retatrutide differs from the approved GLP-1 agents

Approved GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro/Zepbound) are the current clinical standard. Retatrutide adds a third receptor arm: glucagon receptor agonism, which is studied for its thermogenic and energy-expenditure effects. The glucagon pathway is also why retatrutide carries a heart-rate elevation signal in trial data — a safety consideration that does not exist at the same level for semaglutide or tirzepatide. The TRIUMPH program is designed to quantify whether that third receptor meaningfully improves metabolic outcomes over the dual agonist — the head-to-head TRIUMPH-5 data will answer this.

Triple vs dual vs single agonist →

Titan's research-use-only supply

Titan Peptide Lab supplies retatrutide as a lyophilized research vial ($199.99) for in-vitro and laboratory research use only. This is a research compound — not a weight-loss medication, not an FDA-approved drug, and not for human or animal consumption. The TRIUMPH trial data summarized on this page is primary-sourced from published announcements and is reproduced as a research reference for the scientific community monitoring this compound. No Titan product or service is represented as a clinical alternative to any approved medication.

Retatrutide research vial — $199.99 →

The detail, in plain terms

Retatrutide Phase 3 — trial data summary.

Data sourced from Eli Lilly press releases and peer-reviewed publications. Retatrutide is investigational — not FDA-approved. Research use only.

TRIUMPH-1 (n=2,339): Severe obesity; 4/9/12mg vs placebo; 80wk: −17.6%/−23.7%/−25.0% vs −3.9% placebo; 104wk: up to ~30% at 9mg/12mg. Published May 21, 2026.
TRIUMPH-4 interim: ~29% mean weight loss at highest dose; confirmed replicability of TRIUMPH-1 signal.
TRIUMPH-5 (ongoing): Head-to-head Phase 3 vs tirzepatide for obesity. Results pending July 2026.
TRANSCEND-T2D-1: Type 2 diabetes population; 12mg → −16.8% weight at 40 weeks. Published March 2026.
Receptor mechanism: Triple GIP receptor / GLP-1 receptor / glucagon receptor agonist. Half-life ~6 days (weekly dosing). C20 fatty diacid acylation.
FDA designation: Breakthrough Therapy Designation. No NDA filing date announced publicly as of July 2026. Still investigational.
Regulatory comparison: Tirzepatide: FDA-approved (Mounjaro T2D 2022, Zepbound obesity 2023). Semaglutide: FDA-approved (Ozempic/Wegovy). Retatrutide: investigational Phase 3.
Titan supply: Lyophilized research vial, $199.99. Research use only, not for human use.

Questions researchers ask

Before you order.

What did the retatrutide Phase 3 trials show?: The TRIUMPH-1 Phase 3 trial, published May 21, 2026, showed up to 30% mean body-weight reduction at 104 weeks in participants with severe obesity on retatrutide 9mg or 12mg. At 80 weeks, results were 17.6% (4mg), 23.7% (9mg), 25.0% (12mg) versus 3.9% placebo. TRIUMPH-4 confirmed approximately 29% weight loss at the highest dose. TRIUMPH-5 is a head-to-head comparison vs tirzepatide, with results pending.
Is retatrutide FDA-approved?: No. As of July 2026, retatrutide is an investigational compound with Breakthrough Therapy Designation from the FDA. Eli Lilly has not publicly announced an NDA filing date. Breakthrough designation accelerates review but does not guarantee approval and does not authorize any clinical use outside licensed research trials. Retatrutide may not be prescribed or dispensed as a clinical treatment until an NDA is approved.
When will retatrutide be FDA-approved?: There is no confirmed date. Based on the TRIUMPH-1 publication in May 2026 and the standard NDA review timeline (~12 months for Breakthrough Therapy after a Priority Review determination), a regulatory decision could plausibly come in 2027 — but this is speculative. Eli Lilly has not made a public NDA filing announcement as of July 2026. Monitoring Eli Lilly's press releases and FDA's drug approval database is the authoritative source.
How does retatrutide compare to semaglutide and tirzepatide?: Semaglutide (Wegovy) achieved approximately 15–17% weight loss in the STEP trial Phase 3 data. Tirzepatide (Zepbound) achieved approximately 20–22% in the SURMOUNT-1 Phase 3 trial. Retatrutide in TRIUMPH-1 reached approximately 25–30% at 104 weeks — a step up in efficacy at the highest doses. The mechanistic difference: semaglutide targets one receptor (GLP-1), tirzepatide targets two (GLP-1 + GIP), retatrutide targets three (GLP-1 + GIP + glucagon). The glucagon receptor arm adds thermogenic/energy-expenditure effects and also carries a heart-rate elevation signal not seen at the same level with the other agents.
Why does Titan sell retatrutide if it isn't FDA-approved?: Titan Peptide Lab supplies retatrutide as a research-use-only compound for in-vitro laboratory and pre-clinical research settings — the same status as the compound before FDA approval. This is an entirely separate channel from the clinical therapeutic space. Research scientists may legally acquire RUO compounds for research purposes; these are not sold as treatments, substitutes for approved medications, or for any human health purpose. The distinction between RUO supply and clinical use is absolute: Titan's retatrutide is not for human consumption.